FUS immunoreactivity of neuronal and glial intranuclear inclusions in intranuclear inclusion body disease

F. Mori, K. Tanji, T. Kon, S. Odagiri, M. Hattori, Y. Hoshikawa, C. Kono, K. Yasui, S. Yokoi, Y. Hasegawa, M. Yoshida and K. Wakabayashi (2012) Neuropathology and Applied Neurobiology38, 322–328 FUS immunoreactivity of neuronal and glial intranuclear inclusions in intranuclear inclusion body disease Aims: Recent studies have shown that fused‐in‐sarcoma (FUS) protein is a component of ‘neuronal’ intranuclear inclusion bodies (INIBs) in the brains of patients with intranuclear inclusion body disease (INIBD). However, the extent and frequency of FUS‐immunoreactive structures in INIBD are uncertain. Methods: We immunohistochemically examined the brain, spinal cord and peripheral ganglia from five patients with INIBD and five control subjects, using anti‐FUS antibodies. Results: In controls, the nuclei of both neurones and glial cells were intensely immunolabelled with anti‐FUS and neuronal cytoplasm was weakly positive for FUS. In INIBD, neuronal and glial INIBs in the brain and spinal cord were positive for FUS. FUS‐positive INIBs were also found in the peripheral ganglia. The proportion of FUS‐positive neuronal INIBs relative to the total number of inclusion‐bearing neurones ranged from 55.6% to 83.3% (average 73.2%) and that of FUS‐positive glial INIBs ranged from 45.9% to 85.7% (average 62.7%). The nucleus and cytoplasm of inclusion‐bearing neurones and glial cells showed no FUS immunoreactivity. Conclusions: These findings suggest that FUS is incorporated into INIBs in both neurones and glial cells and that loss of normal FUS immunoreactivity may result from reduced protein expression and/or sequestration within inclusions.